Safety Evaluation of a New Preservative in a Lubricating Eye Drop

Johnson & Johnson Consumer and Personal Products Worldwide44 enrolled

Overview

This study is to evaluate the safety of a new preservative in a lubricant eye drop used four times a day in healthy adults and subjects diagnosed with dry eye.

Single-site, open-labeled study. Twenty two subjects will be enrolled into the healthy adult group and twenty two subjects into the dry eye group. Each subject will be in the study for approximately 2 weeks (treatment) and seen at three study Visits: Visit 1 (Day 0, Baseline), Visit 2 (Day 7 +/- 1) and Visit 3 (Day 14 +/- 1). Dosing regimen is 1-2 drops into each eye, four times daily, for two weeks. Assessments will be comprised of visual acuity, slit lamp biomicroscopy, fluorescein corneal staining, and product comfort.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Enrollment

Conditions

Dry Eye Syndromes

Interventions

Eye Drops with Experimental PreservativeOTHER

Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * At least 18 years of age * Able to follow all study instructions and attend all required study visits * Provide written informed consent * Visual health and eye comfort within protocol-specified parameters * Women of child-bearing potential must have a negative urine pregnancy test at screening, not be breast-feeding, and agree to use a protocol-specified acceptable form of birth control throughout the study Exclusion Criteria: * Any medical condition or history, or ocular scores, or use of any drug, device or medication that, per protocol or in the opinion of the investigator, might compromise the safety of the subject or analysis of the study results. * Use of contact lenses outside protocol allowance * Self-reported pregnancy, positive urine pregnancy test, breast-feeding; intends to become pregnant or breast-feed during the duration of the study, refuses protocol-specified urine pregnancy testing, and/or does not use protocol-specified birth control methods and agree to continue doing so for the duration of the study. * Participated in an investigational drug or device trial within 30 days of entering the study.

Locations (1)

ORA, Inc.

Andover, Massachusetts, United States

Outcomes

Primary Outcomes

Post-dose Product Comfort

Product (ocular) comfort was assessed for each eye immediately, and at 1, 2, and 3 minutes following dosing at Visit 1 and 3 using a scale ranging from 0 to 10, where 0 is very uncomfortable and 10 is very comfortable.

Time frame: baseline, Within Two weeks

Change from Baseline in Pre-Dose Visual Acuity

Change from Baseline in Pre-Treatment Means of Pre-Dose Visual Acuity on the LogMAR scale. (The LogMAR scale converts the geometric sequence of a traditional chart to a linear scale. It measures visual acuity loss; positive values indicate vision loss, while negative values denote normal or better visual acuity.)

Time frame: baseline, Within Two weeks

Change from Baseline in Pre-dose Inferior Staining

Means and Differences from Visit 1 in Pre-Dose Inferior Staining

Time frame: baseline, Within Two weeks

Change from Baseline in Mean Corneal Staining

Mean Corneal Staining averaging over the 5 corneal regions and averaging over both eyes (NEI scale 0-3)

Time frame: baseline, Within Two Weeks

Change from Baseline in Pre-Dose Central Staining

Pre-dose Central Staining: Means and Differences from Visit 1

Time frame: baseline, Within Two Weeks

Change from Baseline in Pre-Dose Superior Staining

Pre-Dose Superior Staining: Means and Differences from Visit 1

Time frame: baseline, Within Two Weeks

Change from Baseline in Pre-Dose Temporal Staining

Pre-dose Temporal Staining: Means and Differences from Visit 1

Time frame: baseline, Within Two Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.